RxDoctor Payments Data

Sergei Belkin, MD

Psychiatry · Bayside, NYNPI 1083609762

Payments from drug & device makers

$11,593in general payments, 2019–2025

Across 217 payments — averaging $53.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$2K
  • Neurocrine Biosciences, Inc.$2K
  • Johnson & Johnson$2K
  • Axsome Therapeutics, Inc.$1K
  • Lundbeck LLC$785
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$739
  • plus $3K from 10 others

What the payments were for

  • Food & beverage$11,593100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,593 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$173,588
Medicare patients
329
Services billed
1,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole12$24,969
VyvanseLisdexamfetamine Dimesylate11$4,793
Aripiprazole59$3,138
Oxcarbazepine72$3,085
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$2,971
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$2,452
Memantine Hcl ErMemantine Hcl13$1,766
Bupropion XlBupropion Hcl146$1,431
Trazodone Hcl215$1,283
Clonazepam103$1,271
Gabapentin117$1,261
Methylphenidate ErMethylphenidate Hcl11$1,190
Naltrexone Hcl21$935
Escitalopram Oxalate108$803
Bromocriptine Mesylate12$771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$733$24,96912 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$322$4,79311 claims
Indivior Inc.Suboxone$28$2,97112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Bayside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →